141 related articles for article (PubMed ID: 29974831)
1. Decreased Expression of MYPT1 Contributes to Tumor Angiogenesis and Poor Patient Prognosis in Human Prostate Cancer.
Liang Y; Zhuo Y; Lin Z; Jiang F; Dai Q; Lu J; Dong W; Zhu X; Han Z; Zhong W
Curr Mol Med; 2018; 18(2):100-108. PubMed ID: 29974831
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-30d promotes angiogenesis and tumor growth via MYPT1/c-JUN/VEGFA pathway and predicts aggressive outcome in prostate cancer.
Lin ZY; Chen G; Zhang YQ; He HC; Liang YX; Ye JH; Liang YK; Mo RJ; Lu JM; Zhuo YJ; Zheng Y; Jiang FN; Han ZD; Wu SL; Zhong WD; Wu CL
Mol Cancer; 2017 Feb; 16(1):48. PubMed ID: 28241827
[TBL] [Abstract][Full Text] [Related]
3. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
[TBL] [Abstract][Full Text] [Related]
4. Novel circular RNA circSOBP governs amoeboid migration through the regulation of the miR-141-3p/MYPT1/p-MLC2 axis in prostate cancer.
Chao F; Song Z; Wang S; Ma Z; Zhuo Z; Meng T; Xu G; Chen G
Clin Transl Med; 2021 Mar; 11(3):e360. PubMed ID: 33784000
[TBL] [Abstract][Full Text] [Related]
5. miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer.
Cai C; Chen QB; Han ZD; Zhang YQ; He HC; Chen JH; Chen YR; Yang SB; Wu YD; Zeng YR; Qin GQ; Liang YX; Dai QS; Jiang FN; Wu SL; Zeng GH; Zhong WD; Wu CL
Clin Cancer Res; 2015 Nov; 21(21):4922-34. PubMed ID: 26080838
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
7. Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients.
Liu J; You P; Chen G; Fu X; Zeng X; Wang C; Huang Y; An L; Wan X; Navone N; Wu CL; McKeehan WL; Zhang Z; Zhong W; Wang F
Oncogene; 2016 Apr; 35(14):1750-9. PubMed ID: 26096936
[TBL] [Abstract][Full Text] [Related]
8. SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer.
Yuan D; Wang W; Su J; Zhang Y; Luan B; Rao H; Cheng T; Zhang W; Xiao S; Zhang M; Jiang FN; Sun Z; Jia Z; Zhong WD; Zhu J
Curr Cancer Drug Targets; 2018; 18(9):894-904. PubMed ID: 29295692
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
10. Expression of SOCSs in human prostate cancer and their association in prognosis.
Zhu JG; Dai QS; Han ZD; He HC; Mo RJ; Chen G; Chen YF; Wu YD; Yang SB; Jiang FN; Chen WH; Sun ZL; Zhong WD
Mol Cell Biochem; 2013 Sep; 381(1-2):51-9. PubMed ID: 23666742
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer.
Huang YQ; Han ZD; Liang YX; Lin ZY; Ling XH; Fu X; Cai C; Bi XC; Dai QS; Chen JH; He HC; Chen YR; Jiang FN; Zhong WD
Med Oncol; 2014 Jan; 31(1):820. PubMed ID: 24338276
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer.
Strohmeyer D; Rössing C; Bauerfeind A; Kaufmann O; Schlechte H; Bartsch G; Loening S
Prostate; 2000 Nov; 45(3):216-24. PubMed ID: 11074523
[TBL] [Abstract][Full Text] [Related]
13. Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer.
Guan B; Wu K; Zeng J; Xu S; Mu L; Gao Y; Wang K; Ma Z; Tian J; Shi Q; Guo P; Wang X; He D; Du Y
Oncotarget; 2017 Jan; 8(5):8162-8172. PubMed ID: 28030804
[TBL] [Abstract][Full Text] [Related]
14. Dimethylarginine dimethylaminohydrolase-1 (DDAH1) is frequently upregulated in prostate cancer, and its overexpression conveys tumor growth and angiogenesis by metabolizing asymmetric dimethylarginine (ADMA).
Reddy KRK; Dasari C; Duscharla D; Supriya B; Ram NS; Surekha MV; Kumar JM; Ummanni R
Angiogenesis; 2018 Feb; 21(1):79-94. PubMed ID: 29150732
[TBL] [Abstract][Full Text] [Related]
15. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
16. Pathological significance and prognostic role of microvessel density, evaluated using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy.
Miyata Y; Mitsunari K; Asai A; Takehara K; Mochizuki Y; Sakai H
Prostate; 2015 Jan; 75(1):84-91. PubMed ID: 25307287
[TBL] [Abstract][Full Text] [Related]
17. Fasudil inhibits prostate cancer-induced angiogenesis in vitro.
Chen W; Mao K; Hua-Huy T; Bei Y; Liu Z; Dinh-Xuan AT
Oncol Rep; 2014 Dec; 32(6):2795-802. PubMed ID: 25333508
[TBL] [Abstract][Full Text] [Related]
18. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study.
Vergis R; Corbishley CM; Norman AR; Bartlett J; Jhavar S; Borre M; Heeboll S; Horwich A; Huddart R; Khoo V; Eeles R; Cooper C; Sydes M; Dearnaley D; Parker C
Lancet Oncol; 2008 Apr; 9(4):342-51. PubMed ID: 18343725
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Myosin Phosphatase Target Subunit 1 (MYPT1) Inhibits Tumor Progression and Metastasis of Gastric Cancer.
Wang F; Sun Y
Med Sci Monit; 2018 Apr; 24():2508-2517. PubMed ID: 29687789
[TBL] [Abstract][Full Text] [Related]
20. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
